See more : PT Bank Bisnis Internasional, Tbk (BBSI.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Geron Corporation (GERN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Geron Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- IVS Group S.A. (IVS.MI) Income Statement Analysis – Financial Results
- Impac Mortgage Holdings, Inc. (IMPM) Income Statement Analysis – Financial Results
- Engine Gaming and Media, Inc. (GAME.V) Income Statement Analysis – Financial Results
- Khoon Group Limited (0924.HK) Income Statement Analysis – Financial Results
- Giyani Metals Corp. (CATPF) Income Statement Analysis – Financial Results
Geron Corporation (GERN)
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 237.00K | 596.00K | 1.39M | 253.00K | 460.00K | 1.07M | 1.07M | 6.16M | 36.37M | 1.15M | 1.28M | 2.71M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 6.61M | 5.40M | 6.80M | 7.30M | 5.30M |
| Cost of Revenue | 123.74M | 868.00K | 783.00K | 50.05M | 51.27M | 12.72M | 8.44M | 14.70M | 9.57M | 8.90M | 9.13M | 25.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.65M | -3.70M | -1.70M | -1.60M | -1.20M |
| Gross Profit | -123.50M | -272.00K | 610.00K | -49.80M | -50.81M | -11.66M | -7.37M | -8.53M | 26.80M | -7.75M | -7.85M | -22.47M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 11.26M | 9.10M | 8.50M | 8.90M | 6.50M |
| Gross Profit Ratio | -52,110.97% | -45.64% | 43.79% | -19,683.40% | -11,046.09% | -1,093.53% | -692.21% | -138.48% | 73.68% | -671.99% | -611.93% | -829.42% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 170.40% | 168.52% | 125.00% | 121.92% | 122.64% |
| Research & Development | 125.05M | 95.52M | 85.73M | 51.49M | 52.07M | 13.43M | 11.03M | 18.05M | 17.83M | 20.71M | 23.16M | 51.37M | 69.32M | 61.69M | 57.62M | 53.66M | 54.62M | 41.23M | 35.08M | 30.08M | 25.55M | 31.57M | 29.02M | 23.55M | 20.60M | 15.60M | 15.10M | 14.30M |
| General & Administrative | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Other Expenses | 0.00 | 1.00M | 1.10M | 168.00K | -69.00K | -154.00K | 0.00 | 0.00 | 1.31M | 0.00 | 0.00 | 5.45M | 5.45M | 35.00M | 57.62M | 0.00 | 54.62M | 0.00 | -5.87M | 45.15M | 0.00 | 0.00 | 0.00 | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| Operating Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 37.47M | 29.90M | 21.10M | 19.80M | 18.70M |
| Cost & Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 32.82M | 26.20M | 19.40M | 18.20M | 17.50M |
| Interest Income | 18.15M | 2.53M | 527.00K | 1.83M | 4.22M | 3.29M | 1.42M | 1.19M | 677.00K | 373.00K | 951.00K | 3.10M | 1.02M | 2.05M | 1.37M | 5.54M | 10.79M | 8.70M | 4.66M | 1.55M | 1.81M | 2.55M | 5.86M | 5.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.31M | 6.88M | 3.74M | 760.00K | 0.00 | 0.00 | 77.00K | 83.00K | 88.00K | 82.00K | 56.00K | 233.00K | 237.00K | 98.00K | 143.00K | 93.00K | 102.00K | 130.00K | 464.00K | 672.00K | 736.00K | 757.00K | 1.00M | 12.28M | 0.00 | 900.00K | 0.00 | 400.00K |
| Depreciation & Amortization | 1.03M | 868.00K | 783.00K | 935.00K | 776.00K | 59.00K | 76.00K | 81.00K | 56.00K | 47.00K | 320.00K | 830.00K | 1.58M | 1.61M | 1.75M | 2.42M | 1.93M | 1.59M | 3.74M | 3.91M | 4.12M | 4.59M | 4.37M | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| EBITDA | -174.78M | -134.15M | -111.59M | -73.92M | -67.77M | -26.96M | -29.18M | -30.57M | 803.00K | -35.62M | -38.06M | -67.82M | -95.04M | -109.67M | -68.29M | -59.91M | -62.84M | -47.36M | -35.85M | -32.23M | -26.06M | -31.11M | -30.65M | -21.56M | -17.10M | -10.90M | -9.30M | -11.00M |
| EBITDA Ratio | -73,747.68% | -22,654.19% | -8,010.70% | -29,611.46% | -15,761.96% | -3,051.88% | -2,613.99% | -477.99% | 3.92% | -3,117.00% | -2,823.46% | -2,434.81% | -3,388.72% | -1,160.74% | -4,078.27% | -2,320.37% | -1,001.86% | -1,623.19% | -13,736.21% | 1,226.97% | -2,153.24% | -2,492.79% | -517.65% | -326.21% | 116.67% | -200.00% | -152.05% | -241.51% |
| Operating Income | -193.94M | -138.55M | -114.00M | -76.91M | -72.51M | -31.07M | -29.26M | -30.65M | -559.00K | -36.31M | -38.96M | -71.76M | -96.12M | -111.17M | -70.23M | -67.04M | -62.84M | -47.36M | -37.71M | -81.29M | -30.18M | -35.70M | -35.02M | -26.21M | -20.80M | -12.60M | -10.90M | -12.20M |
| Operating Income Ratio | -81,832.91% | -23,246.64% | -8,183.70% | -30,400.40% | -15,761.96% | -2,914.92% | -2,746.95% | -497.34% | -1.54% | -3,149.35% | -3,036.48% | -2,648.87% | -3,942.41% | -3,120.04% | -4,069.18% | -2,391.87% | -824.44% | -1,445.22% | -13,003.45% | -7,719.37% | -2,570.70% | -2,860.58% | -967.38% | -396.61% | -385.19% | -185.29% | -149.32% | -230.19% |
| Total Other Income/Expenses | 9.82M | -3.35M | -2.11M | 1.30M | 3.96M | 4.06M | 1.34M | 1.11M | 605.00K | 642.00K | 579.00K | 2.88M | -737.00K | -210.00K | 50.00K | 5.02M | 26.14M | 16.00M | 4.18M | 880.00K | 297.00K | 0.00 | -11.91M | 0.00 | -23.40M | 2.70M | 1.80M | 1.80M |
| Income Before Tax | -184.13M | -141.90M | -116.11M | -75.62M | -68.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | 0.00 | -46.93M | 0.00 | -44.20M | -9.90M | -9.10M | -10.40M |
| Income Before Tax Ratio | -77,690.72% | -23,808.89% | -8,335.39% | -29,888.14% | -14,901.74% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | 0.00% | -1,296.38% | 0.00% | -818.52% | -145.59% | -124.66% | -196.23% |
| Income Tax Expense | 0.00 | -868.00K | 4.84M | -7.00K | -5.00M | 4.06M | 1.34M | 1.11M | 32.00K | 35.00K | 56.00K | -597.00K | 5.68M | 31.25M | -3.14M | -5.87M | -26.14M | -16.00M | -4.19M | 44.27M | -297.00K | -1.79M | 7.05M | 19.62M | 25.60M | -1.80M | -1.30M | -1.50M |
| Net Income | -184.13M | -141.03M | -120.95M | -75.61M | -63.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | -33.91M | -42.07M | -45.83M | -46.40M | -10.80M | -9.60M | -10.70M |
| Net Income Ratio | -77,690.72% | -23,663.26% | -8,682.84% | -29,885.38% | -13,815.43% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | -2,716.99% | -1,162.24% | -693.49% | -859.26% | -158.82% | -131.51% | -201.89% |
| EPS | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -2.08 |
| EPS Diluted | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -1.38 |
| Weighted Avg Shares Out | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 158.04M | 153.54M | 127.93M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 5.15M |
| Weighted Avg Shares Out (Dil) | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 162.66M | 153.54M | 128.38M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 7.74M |
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 1,017,000 shares of Geron common stock as inducements to newly hired employees in connection...
Geron: A Strong Launch And Financial Deals Make It Attractive
Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat. Analysts are bullish, with H.C. Wainwright, Leerink, and Goldman Sachs projecting significant sales growth and maintaining high price targets...
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November...
Geron to Participate in the Stifel 2024 Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024 Healthcare Conference, in New York City, on Monday, November 18th,...
Geron: A Post Earnings And Funding Announcement Assessment
Geron Corporation's imetelstat, now branded as Rytelo, was finally approved by the FDA in June for treating lower risk myelodysplastic syndromes and has shown solid initial sales traction. The company just reported third quarter results and announced a new financing...
Geron Corporation (GERN) Q3 2024 Earnings Call Transcript
Geron Corporation (NASDAQ:GERN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Aron Feingold - Vice President of IR and Corporate Communication John Scarlett - Chairman and CEO Jim Ziegler - EVP and CCO Michelle...
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation's (Nasdaq: GERN) RYTELO for $125 million in cash upfront.
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up to $375 million in synthetic royalty and debt financings with Royalty Pharma and investment funds...
Source: https://incomestatements.info
Category: Stock Reports